The EVOLVE and EXPAND study findings were published in 2017. EVOLVE trial The EVOLVE trial analyzed<unk> /ivacaftor in patients with cystic fibrosis, specifically with the homozygous for Phe508del mutation. The EVOLVE trial is a phase 3, double-blinded, multicenter, randomized, placebo-controlled, parallel-group trial, that was which evaluated therapy with a combination of<unk>  and ivacaftor in patients that are 12 and older. 510 patients were randomized and 509 patients were given either 100 mg of<unk>  once daily and 150 mg of ivacaftor twice daily or a placebo for 24 weeks. The combination of drugs was efficacious in patients who had cystic fibrosis with the Phe508del mutation and the adverse effects in both treatment groups were similar.
Tezacaftor
Enarodustat
Vagisil
Sesquimustard
Pretomanid
Androvax
Crofelemer
Clinatec